PL1969007T4 - Kompozycje i sposoby wytwarzania kompozycji - Google Patents

Kompozycje i sposoby wytwarzania kompozycji

Info

Publication number
PL1969007T4
PL1969007T4 PL06848052T PL06848052T PL1969007T4 PL 1969007 T4 PL1969007 T4 PL 1969007T4 PL 06848052 T PL06848052 T PL 06848052T PL 06848052 T PL06848052 T PL 06848052T PL 1969007 T4 PL1969007 T4 PL 1969007T4
Authority
PL
Poland
Prior art keywords
compositions
producing
composition
methods
Prior art date
Application number
PL06848052T
Other languages
English (en)
Other versions
PL1969007T3 (pl
Inventor
Kirk J Leister
Eugene J Schaefer
Ronald Bates
Elizabeth A Bramhall
David M Didio
Robert Donaldson
Alan R Flesher
Helen G Haggerty
David H Kirkley
John M Tabor
Lee K Tay
Pallaiah Thammana
Ajoy Velayudhan
David E Smolin
Reb J Russell
Boom Thomas Vanden
Jeffrey Schrimsher
Joyce Whitehead
Dean Brownell
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38218674&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1969007(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PL1969007T3 publication Critical patent/PL1969007T3/pl
Publication of PL1969007T4 publication Critical patent/PL1969007T4/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL06848052T 2005-12-20 2006-12-19 Kompozycje i sposoby wytwarzania kompozycji PL1969007T4 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US75226705P 2005-12-20 2005-12-20
US75215005P 2005-12-20 2005-12-20
US84954306P 2006-10-05 2006-10-05
PCT/US2006/049074 WO2007076032A2 (en) 2005-12-20 2006-12-19 Compositions and methods for producing a composition
EP06848052.4A EP1969007B1 (en) 2005-12-20 2006-12-19 Compositions and methods for producing a composition

Publications (2)

Publication Number Publication Date
PL1969007T3 PL1969007T3 (pl) 2014-01-31
PL1969007T4 true PL1969007T4 (pl) 2014-04-30

Family

ID=38218674

Family Applications (2)

Application Number Title Priority Date Filing Date
PL06848052T PL1969007T4 (pl) 2005-12-20 2006-12-19 Kompozycje i sposoby wytwarzania kompozycji
PL10153282T PL2253644T3 (pl) 2005-12-20 2006-12-19 Kompozycje i sposoby wytwarzania kompozycji

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL10153282T PL2253644T3 (pl) 2005-12-20 2006-12-19 Kompozycje i sposoby wytwarzania kompozycji

Country Status (24)

Country Link
US (4) US10508144B2 (pl)
EP (2) EP2253644B1 (pl)
JP (2) JP5096369B2 (pl)
KR (2) KR101398713B1 (pl)
CN (1) CN106589132B (pl)
AU (2) AU2006330922B2 (pl)
BR (2) BRPI0620178B1 (pl)
CA (2) CA2836123C (pl)
CY (1) CY1114887T1 (pl)
DK (2) DK1969007T3 (pl)
EA (1) EA017765B1 (pl)
ES (2) ES2433092T3 (pl)
HR (1) HRP20130975T1 (pl)
IL (2) IL192098A (pl)
MX (1) MX336807B (pl)
NO (1) NO20082716L (pl)
NZ (1) NZ597215A (pl)
PE (1) PE20080556A1 (pl)
PL (2) PL1969007T4 (pl)
PT (2) PT2253644E (pl)
SI (2) SI1969007T1 (pl)
TW (2) TWI398520B (pl)
WO (1) WO2007076032A2 (pl)
ZA (1) ZA200805301B (pl)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5096369B2 (ja) 2005-12-20 2012-12-12 ブリストル−マイヤーズ スクイブ カンパニー 組成物および組成物の製造方法
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
ATE525392T1 (de) 2007-01-30 2011-10-15 Epivax Inc Regulatorische t-zellen-epitopen sowie zusammensetzungen damit und anwendungen davon
EP2268805B1 (en) 2008-03-06 2015-05-06 Halozyme, Inc. Large-scale production of soluble hyaluronidase
US7915222B2 (en) 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
BRPI0920030B1 (pt) 2008-10-06 2019-03-26 3-D Matrix, Ltd. Agente de oclusão do tecido, agentes hemostáticos, preventivos e de oclusão ou escleroterapia relacionados, e infusão do tecido mucosal
CN101995476B (zh) * 2009-08-10 2013-07-03 中国医学科学院北京协和医院 临床化学检验用液体质控血清
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
EP2507627A2 (en) 2009-12-04 2012-10-10 Momenta Pharmaceuticals, Inc. Antennary fucosylation in glycoproteins from cho cells
CA2787897A1 (en) * 2010-02-12 2011-08-18 Dsm Ip Assets B.V. Single unit antibody purification
TW201134481A (en) 2010-03-12 2011-10-16 Abbott Biotherapeutics Corp CTLA4 proteins and their uses
US20120121574A1 (en) * 2010-11-15 2012-05-17 Luciano Polonelli Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore
JP5847418B2 (ja) 2011-03-30 2016-01-20 富士フイルム株式会社 細胞接着性タンパク質
JP5987053B2 (ja) * 2011-05-12 2016-09-06 ジェネンテック， インコーポレイテッド フレームワークシグネチャーペプチドを用いて動物サンプルにおける治療抗体を検出するための多重反応モニタリングｌｃ−ｍｓ／ｍｓ法
WO2013130604A1 (en) * 2012-02-27 2013-09-06 Biogen Idec Ma Inc. High-throughput method for sialic acid quantitation
US20150140589A1 (en) * 2012-04-22 2015-05-21 Perfinity Biosciences, Inc. Automated protein digestion, recovery, and analysis
DK2867251T3 (da) * 2012-06-29 2019-11-25 Bristol Myers Squibb Co Fremgangsmåder til reduktion af glycoproteinaggregering
JP6389170B2 (ja) * 2012-07-06 2018-09-12 スリーディー マトリックス， エルティーディー３−Ｄ Ｍａｔｒｉｘ， Ｌｔｄ． ペプチド溶液のためのフィル−フィニッシュ過程
EP2855533A4 (en) * 2013-03-15 2015-11-25 Momenta Pharmaceuticals Inc METHODS RELATING TO CTLA4-FC FUSION PROTEINS
EP2996772B1 (en) 2013-05-13 2018-12-19 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
EP3058084A4 (en) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP3116551B1 (en) 2014-03-10 2022-09-07 3-D Matrix Ltd. Sterilization of peptide compositions
AU2015229549B2 (en) 2014-03-10 2019-05-23 3-D Matrix, Ltd. Self-assembling peptide compositions
US20170042972A1 (en) 2014-04-25 2017-02-16 Chetan KARYEKAR Use of ctla4 compound for achieving drug-free remission in subjects with early ra
JP6948942B2 (ja) * 2014-10-15 2021-10-13 アレクシオン ファーマシューティカルズ， インコーポレイテッド タンパク質産物の等電性プロファイルをシフトさせる方法およびその使用
US9512229B2 (en) * 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
SMT202100467T1 (it) 2015-04-17 2021-09-14 Alpine Immune Sciences Inc Proteine immunomodulatorie con affinità regolabili
MA45481A (fr) 2015-06-10 2018-04-18 Univ Texas Utilisation d'exosomes pour le traitement de maladies
TWI579030B (zh) * 2015-12-15 2017-04-21 Ｃｇ生物技術有限公司 分離細胞之容器、系統及方法
US10814038B2 (en) 2016-01-06 2020-10-27 3-D Matrix, Ltd. Combination compositions
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
US11584932B2 (en) 2016-11-01 2023-02-21 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US10613081B2 (en) * 2016-11-27 2020-04-07 Alireza Palangi Quality control system and kit for automated ELISA devices
EP3639171A4 (en) * 2017-06-16 2021-07-28 Cytiva Sweden AB PROCESS FOR PREDICTING THE RESULT AND MODELING A PROCESS IN A BIOREACTOR
CN109385401A (zh) * 2017-08-10 2019-02-26 北京泰德制药股份有限公司 一种表达重组蛋白的cho细胞的培养方法
WO2019060629A1 (en) * 2017-09-21 2019-03-28 Codiak Biosciences, Inc. PRODUCTION OF EXTRACELLULAR VESICLES IN A SUSPENSION OF INSULATED CELLS USING CHEMICALLY DEFINED CELL CULTURE MEDIA
JP7749319B2 (ja) 2017-10-10 2025-10-06 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用
EP3697810B1 (en) 2017-10-18 2025-12-03 Alpine Immune Sciences, Inc. Variant icos ligand immunomodulatory proteins and related compositions and methods
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
AU2019205273B2 (en) 2018-01-03 2024-04-04 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
JP7102734B2 (ja) * 2018-01-09 2022-07-20 東洋製罐グループホールディングス株式会社 細胞培養方法及び装置
SI3781943T1 (sl) * 2018-04-20 2022-07-29 Janssen Biotech, Inc. Kvalifikacija kromatografske kolone v proizvodnih postopkih za proizvodnjo sestavkov protitelesa proti IL12/IL23
AU2019372675A1 (en) * 2018-11-02 2021-02-04 Beijing Vdjbio Co., Ltd. Modified CTLA4 and methods of use thereof
US11965900B2 (en) * 2018-11-09 2024-04-23 Wyatt Technology, Llc Indicating a status of an analytical instrument on a screen of the analytical instrument
WO2020251862A1 (en) * 2019-06-14 2020-12-17 Agilent Technologies, Inc. Methods and kits to improve the fluorescent signal of dmb-labeled sialic acids
WO2021019295A1 (en) * 2019-07-26 2021-02-04 Jan Remmereit Sialic acid for use in the treatment of psoriasis
CN110554107B (zh) * 2019-08-14 2022-06-10 上海应用技术大学 一种高效液相色谱-质谱联用分析食用油中甘油三酯成分的方法
EP4062176B1 (en) 2019-11-21 2024-05-22 Bristol-Myers Squibb Company Label-free n-glycan quantification methods
CN111398308B (zh) * 2020-03-27 2023-01-17 上海健康医学院 一种片剂、胶囊铝塑泡罩包装质量自动检测方法及系统
JP7415771B2 (ja) 2020-04-24 2024-01-17 株式会社島津製作所 分析支援装置、分析支援方法および分析支援プログラム
JP7314859B2 (ja) 2020-04-30 2023-07-26 株式会社島津製作所 分析支援装置、分析支援方法および分析支援プログラム
CA3182368A1 (en) 2020-05-01 2021-11-04 Kashiv Biosciences, Llc An improved process of purification of protein
JP7415783B2 (ja) * 2020-05-12 2024-01-17 株式会社島津製作所 分析支援装置、分析支援方法および分析支援プログラム
EP4196598A2 (en) * 2020-08-14 2023-06-21 Bristol-Myers Squibb Company Method of making protein
US20230313259A1 (en) * 2020-08-14 2023-10-05 Bristol-Myers Squibb Company Manufacturing process for protein
CN112198302B (zh) * 2020-10-25 2022-12-16 中铁二局第一工程有限公司 一种细集料含泥量快速检测方法及测量工具
EP4281542A1 (en) * 2021-01-20 2023-11-29 Regeneron Pharmaceuticals, Inc. Methods of improving protein titer in cell culture
WO2022198304A1 (en) * 2021-03-25 2022-09-29 Lumex Instruments Canada (0890278 B.C. Ltd.) Device for electrophoretic analysis of multicomponent liquid samples
EP4314044A4 (en) * 2021-03-31 2025-02-12 Dr. Reddy's Laboratories Limited CELL CULTURE METHODS FOR FUSION PROTEIN ASSEMBLY
CN113241192B (zh) * 2021-05-18 2023-06-20 武汉大学中南医院 一种证据合成方法和计算机设备
JP7600875B2 (ja) * 2021-06-01 2024-12-17 株式会社島津製作所 試料分析装置、試料分析方法、医薬分析装置および医薬分析方法
AU2022358612A1 (en) * 2021-09-28 2024-04-11 Kashiv Biosciences, Llc An improved process of purification of fusion protein
CA3233419A1 (en) * 2021-09-28 2023-04-06 Kashiv Biosciences, Llc An improved process for purification of protein
WO2023053032A1 (en) * 2021-09-28 2023-04-06 Kashiv Biosciences, Llc An improved process for purification of fusion protein
JP2025500887A (ja) * 2021-12-16 2025-01-15 ブリストル－マイヤーズ スクイブ カンパニー ウイルス不活化用界面活性剤
JP2025016812A (ja) * 2021-12-16 2025-02-05 レグセル株式会社 免疫系の異常に関連する疾患、障害または症状を処置するための医薬組成物
EP4441496A4 (en) * 2021-12-17 2025-12-24 Kashiv Biosciences Llc IMPROVED PROCESS FOR SEPARATION OF LOW MOLECULAR WEIGHT PROTEINS
US20250206775A1 (en) * 2022-03-18 2025-06-26 Bristol-Myers Squibb Company Methods of isolating polypeptides
CN116467264B (zh) * 2023-04-14 2025-11-28 阿里健康科技(中国)有限公司 Rf2文件的生成方法、装置、设备和存储介质
US12461955B2 (en) * 2023-09-08 2025-11-04 Salesforce, Inc. Integration flow generation using large language models
CN117044627B (zh) * 2023-10-11 2023-12-15 中国科学院昆明植物研究所 一种高山植物塔黄的组培快繁及离体保存方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4460694A (en) * 1981-03-26 1984-07-17 University Of Miami Bovine glycoproteins and use in diagnosing infectious mononucleosis
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
US5856298A (en) 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
EP0606217B2 (en) 1991-06-27 2008-12-03 Bristol-Myers Squibb Company Ctl4a receptor, fusion proteins containing it and uses thereof
US6090914A (en) 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
WO1993010260A1 (en) * 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US5456909A (en) 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US6084067A (en) 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
JPH09502728A (ja) * 1993-09-15 1997-03-18 アルファ セラピューティク コーポレイション α▲下１▼−酸性糖タンパク質の精製方法及び精製物
US5451660A (en) * 1993-12-13 1995-09-19 Genentech, Inc. Method for purifying polypeptides
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
WO1995034320A2 (en) 1994-06-07 1995-12-21 Regents Of The University Of Minnesota Methods for inhibiting antigen specific t cell responses
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US6656466B1 (en) * 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
WO1997004801A1 (en) 1995-07-27 1997-02-13 Genentech, Inc. Stabile isotonic lyophilized protein formulation
CA2268747A1 (en) 1996-11-15 1998-05-22 Genentech, Inc. Purification of neurotrophins
DK1897890T3 (da) 1996-11-27 2010-04-06 Genentech Inc Affinitetsoprensning af polypeptid på en protein A matrix
ZA98533B (en) 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US20030124614A1 (en) 1997-08-29 2003-07-03 Brighams And Womens Hospital Inc. Novel T-cell membrane protein (TIRC7), peptides and antibodies derived therefrom and uses thereof
AU2051899A (en) 1997-12-03 1999-06-16 Roche Diagnostics Gmbh Method for preparing polypeptides with appropriate glycosilation
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
EP1500661A1 (en) 1998-06-01 2005-01-26 Genetech, Inc. Separation of protein monomers from aggregates by use of ion-exchange chromatography
US6521419B1 (en) 1998-09-22 2003-02-18 Kanakaraju Koduri Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6800457B2 (en) 1998-09-22 2004-10-05 Bristol-Myers Squibb Company Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
ES2281342T3 (es) 1999-04-26 2007-10-01 Genentech, Inc. Proceso de cultivo de celulas para la produccion de glicoproteinas.
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
DE60141657D1 (de) * 2000-03-27 2010-05-06 Genetics Inst Llc Verfahren zur Reinigung von stark anionischen Proteinen
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
SI1248802T1 (en) 2000-05-26 2005-02-28 Bristol-Myers Squibb Co. Soluble ctla4 mutant molecules and uses thereof
AU2001275411B2 (en) 2000-06-09 2005-04-28 Bristol-Myers Squibb Company Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion
AU2001272978A1 (en) 2000-06-23 2002-01-08 Maxygen, Inc. Novel co-stimulatory molecules
US7183376B2 (en) * 2000-06-23 2007-02-27 Maxygen, Inc. Variant B7 co-stimulatory molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
UY26815A1 (es) 2000-07-03 2002-01-31 Bristol Myers Squibb Co Métodos para tratar enfermedades reumáticas al usar una molécula ctla4 soluble
US6358265B1 (en) 2000-07-18 2002-03-19 Specialized Health Products, Inc. Single-step disposable safety lancet apparatus and methods
MXPA03006699A (es) 2001-01-26 2004-05-31 Univ Emory Metodos de induccion de tolerancia al trasplante de organos y correccion de hemoglobinopatias.
CZ305380B6 (cs) 2001-05-23 2015-08-26 Bristol-Myers Squibb Company Léčivo pro inhibici rejekce transplantovaných buněk ostrůvků slinivky břišní
WO2003080852A1 (en) * 2002-03-26 2003-10-02 Lek Pharmaceutical And Chemical Company D.D. Process for the preparation of a desired erythropoietin glyco-isoform profile
ES2557741T3 (es) 2002-03-27 2016-01-28 Immunex Corporation Procedimientos para incrementar la producción de polipéptidos
US20040259150A1 (en) * 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
EP1496931A4 (en) 2002-04-19 2009-07-01 Bristol Myers Squibb Co METHODS OF TREATING AUTOIMMUNE DISEASE USING SOLUBLE CTLA4 MOLECULE AND ARMM OR NSAID
CA2478925C (en) 2002-04-26 2016-06-07 Robert Lee Fahrner Non-affinity purification of proteins
TR200302265T1 (tr) 2002-06-19 2004-08-23 Eös Eczacibaşi Özgün Ki̇myasal Ürünler San. Ve Ti̇c. A.Ş. Sübstitiye fenil eterlerin üretimi için proses
SI1543106T1 (sl) * 2002-07-15 2007-08-31 Immunex Corp Postopki in mediji za nadziranje sialilacije proteinov, ki jih proizvajajo sesalske celice
US6924124B1 (en) 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
TWI328614B (en) * 2002-12-23 2010-08-11 Bristol Myers Squibb Co Product quality enhancement in mammalian cell culture processes for protein production
TWI312368B (en) 2002-12-23 2009-07-21 Bristol Myers Squibb Compan Mammalian cell culture processes for protein production
ZA200507757B (en) 2003-04-04 2007-01-31 Genentech Inc High concentration antibody and protein formulations
US7118222B2 (en) * 2003-05-12 2006-10-10 Seiko Epson Corporation Optical device and protector
DE602004029252D1 (de) * 2003-06-13 2010-11-04 Biogen Idec Inc Aglycosyl-anti-cd154 (cd40-ligand) antikörper und deren verwendungen
CA2762015A1 (en) * 2003-08-04 2005-02-24 Bristol-Myers Squibb Company Methods for treating cardiovascular disease using a soluble ctla4 molecule
AU2004285928B2 (en) * 2003-10-24 2012-02-02 Amgen, Inc. Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction
RU2370276C2 (ru) 2003-12-31 2009-10-20 Мерк Патент Гмбх Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
US7253167B2 (en) 2004-06-30 2007-08-07 Bristol-Myers Squibb Company Tricyclic-heteroaryl compounds useful as kinase inhibitors
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP5096369B2 (ja) * 2005-12-20 2012-12-12 ブリストル−マイヤーズ スクイブ カンパニー 組成物および組成物の製造方法
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
AU2006330593B2 (en) 2005-12-20 2012-07-26 Bristol-Myers Squibb Company Stable protein formulations
AU2007291282B2 (en) 2006-08-28 2011-10-20 Ares Trading S.A. Process for the purification of Fc-fusion proteins
CA2661748C (en) 2006-08-28 2016-02-09 Alex Eon-Duval Process for the purification of fc-containing proteins

Also Published As

Publication number Publication date
JP5097194B2 (ja) 2012-12-12
JP2009520503A (ja) 2009-05-28
EA017765B1 (ru) 2013-03-29
CA2836123C (en) 2017-09-12
NO20082716L (no) 2008-09-19
HK1121173A1 (en) 2009-04-17
US20190092835A1 (en) 2019-03-28
JP2010116402A (ja) 2010-05-27
HRP20130975T1 (hr) 2013-11-22
TWI398520B (zh) 2013-06-11
KR20120010275A (ko) 2012-02-02
TWI423986B (zh) 2014-01-21
ES2439641T3 (es) 2014-01-24
IL229904A0 (en) 2014-01-30
SI2253644T1 (sl) 2014-03-31
CA2836123A1 (en) 2007-07-05
US10941189B2 (en) 2021-03-09
EP2253644A1 (en) 2010-11-24
EP1969007A2 (en) 2008-09-17
WO2007076032A3 (en) 2008-04-03
AU2010241289A1 (en) 2010-12-02
US10808021B2 (en) 2020-10-20
PL2253644T3 (pl) 2014-04-30
US12030923B2 (en) 2024-07-09
KR20080090428A (ko) 2008-10-08
PT1969007E (pt) 2013-12-10
BRPI0622251A2 (pt) 2011-07-19
ES2433092T3 (es) 2013-12-09
WO2007076032A2 (en) 2007-07-05
EA200801571A1 (ru) 2010-02-26
KR101391457B1 (ko) 2014-05-19
AU2006330922A1 (en) 2007-07-05
EP2253644B1 (en) 2013-10-16
MX336807B (es) 2016-02-02
PT2253644E (pt) 2014-01-23
DK1969007T3 (da) 2013-11-25
CA2634760C (en) 2014-09-09
US20090252749A1 (en) 2009-10-08
US20190062399A1 (en) 2019-02-28
CN106589132A (zh) 2017-04-26
CY1114887T1 (el) 2016-12-14
US20210246188A1 (en) 2021-08-12
TW201313742A (zh) 2013-04-01
JP5096369B2 (ja) 2012-12-12
AU2010241289B2 (en) 2012-09-13
DK2253644T3 (da) 2014-01-13
TW200745334A (en) 2007-12-16
NZ597215A (en) 2012-11-30
IL192098A (en) 2014-01-30
PL1969007T3 (pl) 2014-01-31
CA2634760A1 (en) 2007-07-05
IL192098A0 (en) 2008-12-29
BRPI0620178A2 (pt) 2010-06-29
CN106589132B (zh) 2022-03-29
AU2006330922B2 (en) 2012-07-26
EP1969007B1 (en) 2013-08-28
SI1969007T1 (sl) 2014-03-31
KR101398713B1 (ko) 2014-06-12
PE20080556A1 (es) 2008-06-13
US10508144B2 (en) 2019-12-17
BRPI0620178B1 (pt) 2022-08-23
ZA200805301B (en) 2012-11-28

Similar Documents

Publication Publication Date Title
IL229904A0 (en) Preparations and methods for producing a compound
GB0522658D0 (en) Composition
GB0522287D0 (en) Method and compositions
IL184834A0 (en) Compositions and methods for the manufacture thereof
GB0519164D0 (en) Composition
ZA200806434B (en) Calcium-enrichment compositions and methods for production thereof
GB0507167D0 (en) Composition
GB0508250D0 (en) Composition
GB0506044D0 (en) Composition
EP1847249A4 (en) hair dye
EP1845979A4 (en) METHOD AND COMPOSITIONS FOR REDUCING STORAGE PRODUCTION
IL185516A0 (en) A composition
EP1860069A4 (en) PROCESS FOR PREPARING A COMPOSITION
GB0524927D0 (en) Compositions and method
EP1947129A4 (en) PHOTORADIC AND PHOTOCYSTIC CURING COMPOSITION
GB0525592D0 (en) A composition
GB0511235D0 (en) Compositions and method
GB0502341D0 (en) Composition
GB0513641D0 (en) Anti-egeing composition
GB0510286D0 (en) Composition
GB0502889D0 (en) Novel method and compositions
IL175683A0 (en) Constrained model composition
GB0517170D0 (en) Composition
GB0515017D0 (en) Composition
GB0525748D0 (en) Composition